SILO Silo Pharma: Rasio rega marang prakiraan pendapatan

Tandha merek Silo Pharma, Inc. (SILO)

Silo Pharma, Inc. (SILO) relies on investments as it lacks a stable cash flow. The projected P/S level on the GURU.Markets terminal chart visualizes this imbalance, where 87.10 reflects the latest metric value. While the nasal drug SPC-15 for PTSD offers growth prospects, strict DEA oversight and the risk of failed trials create significant barriers for the biotech firm.

Silo Pharma - Rasio kapitalisasi marang dodolan sing dikarepake SILO (periode 28.04.2023 - 15.11.2026)

SILO (Silo Pharma, Inc.): rincian analitis lan laporan miturut indikator

- rega pasar lan target rega analis:
Bagan rega silopharma.com|SILO - Rata-rata rega prakiraan
- data kapitalisasi saham perusahaan:
Nilai pasar Silo Pharma|SILO - Rega Tumbas Perusahaan
- indikator nilai buku ekuitas:
Nilai Buku saben Saham Silo Pharma|SILO - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku silopharma.com|SILO - Aset Agregat Perusahaan
- data liabilitas lan likuiditas perusahaan:
Utang marang Ekuitas Silo Pharma, Inc.|SILO - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Silo Pharma|SILO - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Silo Pharma|SILO - Kewajiban jangka dawa|Utang jangka cendhak perusahaan Silo Pharma|Rasio cepet silopharma.com
- rincian asil keuangan lan kelipatan valuasi:
SILO - Bathi resik|Bathi sing dikarepake Silo Pharma, Inc.|SILO - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep Silo Pharma Inc.|SILO - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA Silo Pharma|SILO - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Silo Pharma|SILO - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan silopharma.com|SILO - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Silo Pharma, Inc.
- indikator volume dodolan lan pendapatan:
SILO - Volume dodolan perusahaan|Prakiraan volume dodolan silopharma.com|SILO - Kapitalisasi marang pendapatan|Multiplikator forward rega marang pendapatan Silo Pharma
Ringkesan analisis perusahaan:SILO (Silo Pharma)
Produk asli Silo Pharma Inc.

Silo Pharma, Inc. (SILO) is developing innovative therapies for neurodegenerative pathologies based on psilocybin formulations. By analyzing the company's P/S expectations, an investor assesses market capitalization relative to projected revenue, which allows them to filter out speculative noise and determine a fair discount for future cash flows from clinical trials, thereby confirming the long-term fundamental stability of the business.

Pesaing langsung

Rasio rega marang prakiraan pendapatan alkermes.com ALKS|Avadel Pharma (AVDL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|atai - Multiplikator Forward P/S|Prakiraan rega marang pendapatan GH Research PLC (GHRS)|MNMD: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep COMPASS Pathways PLC (CMPS)|Multiplikator forward rega marang pendapatan LBRX|Bright Minds Biosciences Inc (DRUG) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S VNDA|Rasio kapitalisasi marang dodolan sing dikarepake Cybin Inc|Alto Neuroscience - Multiplikator forward rega marang pendapatan|NRXP (NRx Pharmaceuticals, Inc.) - Rega mangsa ngarep marang pendapatan|CING - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan CPHI (China Pharma Holdings, Inc.)|CMND: Multiplikator Forward P/S|Psyence Biomedical Ltd. - Rega forward marang dodolan|SPRC (SciSparc Ltd.) - Multiplikator Forward P/S|SEEL (Seelos Therapeutics, Inc.) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S VRPX|KRTX (Karuna) - Rega forward marang dodolan